Supplemental Table 1. Profile of patients in the study.

	Standard Arm N = 10	Investigational Arm N = 9
Mean Age in Years [Range]	48 [37–55]	46 [38–54]
Male Gender [%]	9 [90%]	7 [78%]
Il28b- CC haplotype	2 [20%]	2 [22%]
Race		
● Black	6 [60%]	5 [56%]
● White	2 [20%]	2 [22%]
● Asian	1 [10%]	0 [0%]
● Hispanic	1 [10%]	2 [22%]
Risk Factor		
● IVDU	5 [50%]	6 [67%]
● Sexual	4 [40%]	2 [22%]
● Combined	0 [0%]	1 [11%]
● Other	1 [10%]	0 [0%]
HCV Genotype		
● 1a	8 [80%]	6 [67%]
● 1b	2 [20%]	2 [22%]
● 1 other	0 [0%]	1 [11%]
Mean HCV $\log_{10}$ IU/ml [range]	5.84 [4.80–6.60]	5.27 [3.89–6.29]
Mean CD4 Count [range]	514 [127–1167]	554 [181–907]
HAART therapy	9 [90%]	6 [67%]
HIV VL suppression	8 [80%]	5 [56%]

Patients with other causes of liver disease, advanced cirrhosis or severe liver decompensation, severe psychiatric disorder, active alcohol/substance abuse that would interfere with compliance, severe cardiopulmonary or renal disorder, severe retinopathies hemoglobinopathies or who were receiving treatment with steroids or other immunosuppressants were excluded.